Other News To Note
Monday, January 28, 2013
Kineta Inc., of Seattle, said it secured exclusive, worldwide development rights from the University of Utah Research Foundation to a portfolio of drug candidates based on the Conotoxin Rg1a for the non-narcotic treatment of chronic pain.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.